FDA spurns Supernus for Parkinson's drug, noting application issues 'across several areas'

Supernus has found itself in the crosshairs of the FDA once again.

A pitch for a Parkinson’s disease treatment was rejected by regulators, the biotech announced Monday, sending it back to the application drawing board. The rejection is not the first time this program, dubbed SPN-830, has faced scrutiny: Supernus previously received an RTF for it back in November 2020.